Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › UBT251 phase 2 obesity China (NCT07177469)

UBT251 phase 2 obesity China (NCT07177469)

UBT251 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
UBT251
Population
obesity
Phase
2
Participants
205
Duration
24 weeks
Registry
NCT07177469

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
4.0 mg (initial dose 0.5 mg)obesity china24205——−16.2 % vs −2.0 %
estimand not specified
———————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (1)
  • 4.0 mg (initial dose 0.5 mg) · weight_unsp · abstract
    change (95% CI) in weight being -13.6% (-15.3 to -11.8) in the 2.0 mg group, -16.2% (-18.7 to -13.6) in the 4.0 mg (ID, 0.5 mg)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: UBT251 phase 2 obesity China (NCT07177469). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/ubt251-phase-2-obesity-china/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.